Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, MaxCyte, Inc. reported revenue of $33M, down 14.5% year over year. Operating margin was -157.1% and net margin -135.1%, on a free-cash-flow margin of -109.5% with capital expenditure at 5.4% of revenue. Every figure is computed directly from MXCT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $33M | -157.1% | -135.1% |
| FY2024 | $39M | -132.5% | -106.3% |
| FY2023 | $41M | -117.0% | -91.8% |
| FY2022 | $44M | -61.8% | -53.3% |
| FY2021 | $34M | -53.7% | -56.3% |
How does MXCT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: IQV · ACM · BAH · ICLR · PAYX · IT
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.